BioWorld - Saturday, November 26, 2022

Drug design, drug delivery and technologies, BioWorld Science
Drug design, drug delivery and technologies, BioWorld Science RSS Feed RSS

Scientist, microscope and dropper
Drug Design, Drug Delivery & Technologies

Nona and Dragonfly establish drug discovery collaboration

Nov. 21, 2022
No Comments
Nona Biosciences, a wholly owned subsidiary of HBM Holdings Ltd., has entered into a collaboration agreement with Dragonfly Therapeutics Inc. based on Nona's proprietary fully human heavy chain only antibody (HCAb) transgenic mice platform to discover and develop fully human heavy chain only antibodies for bispecific/multi-specific therapeutic antibody generation.
Read More
Cancer

Advances in cancer research trap the impenetrable MYC

Nov. 9, 2022
By Mar de Miguel
No Comments
Myc-associated factor X (MAX), the protein that forms dimers with Myc, could hold the key to blocking one of the most intractable oncogenes. Scientists at the University of Chicago have designed a synthetic molecule that effectively mimics a module of MAX's binding domain. In parallel, the Omomyc protein OMO-103, developed by researchers at the Vall d'Hebron Institute of Oncology (VHIO) in Barcelona, successfully completed a phase I clinical trial. From different therapeutic perspectives, both approaches corner Myc and predict the advance of this slow line of research.
Read More
Magnetic bacteria
Drug Design, Drug Delivery & Technologies

Magnetic attraction makes bacteria better drug delivery vehicles

Nov. 7, 2022
By Nuala Moran
No Comments
A new method for controlling naturally magnetized bacteria has improved the prospects of applying them as vehicles for intratumoral delivery of cancer drugs and in hyperthermia therapy. The advance will provide a better way of directing the movement of systemically administered bacteria, using external magnetic fields to target them to tumors sited deep in the body. It also points to a possible route for engineering existing bacteria-based anticancer constructs for better targeting.
Read More
Cancer

Immunogenic molecule also affects mitochondria, broadening clinical potential

Nov. 2, 2022
By Mar de Miguel
No Comments
Researchers from the University of Zaragoza and Promontory Therapeutics Inc. have discovered that PT-112, which has a multimodal mechanism of action, could have different clinical applications in cancer treatment due to its effects on mitochondria in castration-resistant prostate cancer (CRPC). PT-112 is an immunogenic small molecule currently in phase II development in metastatic castration-resistant prostate cancer (mCRPC). The researchers designed PT-112 to target advanced solid tumors, such as thymus, small-cell, non-small-cell lung or CRPC.
Read More
The Combat of Rama and Ravana.
Cancer

ENA 2022: Mutant specific or target selective, that is the question for drug development

Oct. 27, 2022
By Mar de Miguel and Anette Breindl
No Comments
Diwali, the Festival of Light, marks different events depending on where it is celebrated. In some areas of India, it marks the return of Lord Rama to his birthplace of Ayodhya after defeating the demon Ravana. For Vivek Subbiah, associate professor at the Department of Investigational Cancer Therapeutics, Division of Cancer Medicine of the MD Anderson Cancer Center, the story of how Rama defeated Ravana has parallels in drug discovery. Ravana had 10 heads, and when one was cut off, it grew back. Rama defeated Ravana by means of a magic arrow that entered through the demon’s navel.
Read More